Dare Bioscience, Inc. quarterly report, Q2 FY2014

Dare Bioscience, Inc. — Filing Summary

Important identity discrepancy: The supplied filing is Cerulean Pharma Inc.’s Form 10-Q for the quarter ended June 30, 2014, not a filing identified as Dare Bioscience, Inc. Verify the issuer and filing before relying on this summary.

Business context and reporting period

The unaudited report covers the three and six months ended June 30, 2014, with comparisons to 2013. Cerulean described itself as a clinical-stage oncology company developing nanoparticle-drug conjugates. It had no product sales and reported only small amounts of research-related revenue.

Financial results and liquidity

MetricThree months ended June 30, 2014Six months ended June 30, 2014
Revenue$33,000$80,000
Research and development expense$2.648 million$4.143 million
General and administrative expense$2.029 million$3.539 million
Operating loss$4.644 million$7.602 million
Net loss$7.403 million$10.317 million
Net cash used in operating activitiesNot presented for the quarter$7.895 million

Revenue was immaterial relative to expenses, so a meaningful operating margin is not apparent. At June 30, cash and cash equivalents were $64.271 million, versus $5.488 million at December 31, 2013. Current assets were $65.394 million and current liabilities $5.963 million. The company reported an accumulated deficit of $108.756 million.

Cash increased by $58.783 million in the first half, largely reflecting $59.861 million of net IPO proceeds and $8.322 million of net proceeds from convertible notes, partly offset by operating cash use and debt repayments. Outstanding Lighthouse loan principal was $5.0 million; the balance sheet showed $4.725 million of current and long-term loan payable. The loan bears 8.25% interest, is secured by substantially all assets other than intellectual property, and includes restrictive covenants.

Material changes versus the prior comparable period

  • Second-quarter net loss widened by $2.510 million from 2013, primarily due to a $2.493 million noncash loss recorded when convertible notes converted to common shares at the IPO.
  • First-half net loss improved by $148,000 year over year. Operating loss improved by $2.436 million, mainly as R&D expense fell 38% to $4.143 million; the improvement was largely offset by higher other expense, including the note-conversion loss.
  • Second-quarter R&D declined 17% year over year. CRLX101 spending rose 44% to $1.875 million as a randomized Phase 2 renal-cell-carcinoma trial began; CRLX301 and platform spending fell.
  • G&A increased 46% in the quarter, attributed mainly to public-company costs. First-half G&A was up 5%.
  • The April 2014 IPO and over-allotment sale raised approximately $59.9 million net. Preferred stock and convertible notes converted into common stock, substantially increasing shares outstanding and affecting per-share comparability.

Outlook, commentary, and risks

  • Management estimated that June 30 cash would fund operating expenses, debt service, and capital expenditures into the first quarter of 2016. This estimate depends on assumptions that may prove incorrect; management said additional capital would be needed for certain planned trials and later development.
  • Plans included ongoing CRLX101 trials, a CRLX301 Phase 1 trial by the end of 2014, and potential randomized Phase 2 CRLX101 trials in ovarian and neoadjuvant rectal cancer in 2015, contingent on trial results. These are plans, not guaranteed milestones. No formal financial guidance was provided.
  • The company expected R&D and public-company costs to increase. It had never been profitable, expected continuing losses, and said it might need equity, debt, or collaboration financing, with potential dilution or licensing of valuable rights.
  • Material development risks include an earlier CRLX101 Phase 2 NSCLC trial that failed its primary overall-survival endpoint; uncertain preliminary investigator-sponsored-trial results; clinical, regulatory, enrollment, safety, and manufacturing risks; and the possibility that products never receive approval or achieve commercial acceptance.
  • Manufacturing is outsourced; the filing notes a 2013 CRLX301 batch-contamination issue and delays obtaining a replacement batch. Calando, a key licensor, had entered Chapter 7 bankruptcy, creating potential license-related uncertainty.
  • Contingent obligations include up to $32.8 million in CRLX101 regulatory and commercial milestones and up to $17.8 million in CRLX301 milestones, plus royalties and possible sublicense-income payments. A July 2014 lease amendment added approximately 8,628 square feet and $514,000 of base rent through February 2016.
  • After the reporting date, management cited no material change in planned IPO-proceeds use. The report states that disclosure controls were effective and that there were no material changes in internal control over financial reporting during the quarter.

Investor facts to verify

  • Confirm the issuer: the source names Cerulean Pharma Inc., while the request names Dare Bioscience, Inc.
  • Check subsequent cash burn, financing needs, and whether the stated runway into Q1 2016 proved achievable.
  • Verify clinical-trial status and results for CRLX101 and CRLX301, including the planned CRLX301 trial and the reported prior CRLX101 NSCLC failure.
  • Review debt covenants and repayment terms, Calando license and bankruptcy developments, and the status of milestone, royalty, and lease obligations.
  • Assess share-count changes, dilution, and potential insider or early-investor share sales following the IPO lock-up expiration.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.